GlobeNewswire

Nexstim Plc: Decisions of the Board of Directors regarding issuance of shares under the restricted share unit plan and directed share issue

Share

Company announcement, Helsinki, 14June2021 at 3:30 PM (EEST)

Nexstim Plc: Decisions of the Board of Directors regarding issuance of shares under the restricted share unit plan and directed share issue

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that pursuant to the authorisation received from the Company's Annual General Meeting on May 11, 2021 and the restricted share unit reward plan approved by the Annual General Meeting on 26 March 2016, the Board of Directors of the Company has today resolved on issuing altogether 46 057 new shares without payment to members of the Board of Directors. Leena Niemistö will receive 12 960 shares, Martin Forss will receive 8 316 shares, Rohan Hoare will receive 13 260 shares and Tomas Holmberg will receive 11 521 shares based on the amount of the gross reward for the vesting period 2020-2021 determined by the Annual General Meeting on 30 April 2020.

The new shares are expected to be listed on or about 18 June 2021. After the issuance, the total number of shares in the Company will be 6 686 673.

NEXSTIM PLC

Board of Directors

Further information is available on the website www.nexstim.com, or by contacting:

Leena Niemistö, Chair of Board
+358 9 2727 179
leena.niemisto@nexstim.com

Erik Penser Bank AB (Certified Adviser)
 +46 8 463 83 00
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scientists Narrow Search For Mysterious Mad Trapper To Sweden30.7.2021 23:21:41 CEST | Press release

EDMONTON, Alberta and HOUSTON, July 30, 2021 (GLOBE NEWSWIRE) -- This month marks the 90th anniversary of the arrival of the fugitive known as ‘The Mad Trapper of Rat River’ to the Canadian North and the revelation of an important new clue to identifying the mysterious fugitive. Following the unprovoked shooting of RCMP Constable A.W. King in December 1931, the unknown criminal who identified himself by the pseudonym Albert Johnson led an RCMP posse on seven-week manhunt across the desolate Arctic landscape. During the pursuit, the Mad Trapper shot and killed Constable E. Millen. With the help of indigenous guides the Mad Trapper was located and killed during a gun battle on the Eagle River on February 17, 1932. Despite the RCMP releasing photos of the Mad Trapper and receiving hundreds of tips from around the world his identity was never established In 2007, Myth Merchant Films of Alberta Canada secured permission for a team of forensic experts to exhume the body of the Mad Trapper in

KBC Group: KBC remains strongly capitalised under 2021 EU-wide EBA stress test30.7.2021 18:15:00 CEST | Press release

Press Release Outside trading hours - Regulated information* Brussels, 30 July 2021 (6.15 p.m. CEST) KBC remains strongly capitalised under 2021 EU-wide EBA stress test KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2021 EU-wide stress test. A brief set of slideson the KBC data is available at www.kbc.com. The impact of the stress test on KBC’s fully loaded Common Equity Tier-1 (CET1) ratio of 17.58% at year-end 2020 caused this ratio to increase by 1.92 percentage points to 19.50% at year-end 2023 under the base scenario. Under the adverse scenario, KBC’s fully loaded CET1 ratio would fall by 3.51 percentage points to 14.07%1. KBC’s leverage ratio, which stood at 6.42% at year-end 2020, would increase to 7.09% under the base scenario and decrease to just 5.53% under the adverse scenario. Commenting on today’s announcements, Johan Thijs, KBC Group CEO had this to say: ‘The results of this regular, theoretical exercise conduct

EBA reports on outcome of 2021 EU-wide stress test30.7.2021 18:10:23 CEST | Press release

EBA reports on outcome of 2021 EU-wide stress test ING Group was subject to the 2021 EU-wide stress test conducted by the European Banking Authority (EBA), in cooperation with the European Central Bank (ECB), the European Systemic Risk Board (ESRB) and De Nederlandsche Bank. ING Group notes the announcements made today by the EBA on the stress test and fully acknowledges the outcomes of this exercise. The 2021 EU-wide stress test does not contain a pass/fail threshold and instead is designed to be used as an important source of information for the purposes of the Supervisory Review and Evaluation Process. The results will assist competent authorities in assessing ING Group’s ability to meet applicable prudential requirements under stressed scenarios. The adverse stress test scenario was set by the ECB/ESRB and covers a three-year time horizon (2020-2023). The stress test has been carried out applying a static balance sheet assumption as at December 2020, and therefore does not take int

XBiotech Announces Payment of Dividend to Holders of Common Stock30.7.2021 17:03:00 CEST | Press release

Company distributed USD $75 Million to Shareholders AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech’s balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug candidates. John Simard stated that “XBiotech was pleased to be able to reward its shareholders with a $2.47 per share dividend. Our ability to continue to provide opportunities for shareholders to monetize stock in XBiotech, reflects the strength of

Jānis Buks elected as the Chairperson of the Management Board of JSC Olainfarm30.7.2021 12:41:00 CEST | Press release

Today, on July 30, the Supervisory Council of JSC Olainfarm has elected Jānis Buks as the Chairperson of the Management Board. He has significant professional experience, which, together with the team of JSC Olainfarm, will contribute to the company's growth, stability, and predictability. Jānis Buks was the Deputy Chairperson of the Supervisory Council of JSC Olainfarm from April 4, 2019 to June 17, 2021. “JSC Olainfarm is a Latvian pharmaceutical success story, however, the conflicts of recent years have overshadowed the success. We need to ensure stability and predictability, both for future plans and for the group as a whole. It is time to restart Olainfarm and build back the company's reputation, continue to grow and to be a stable and predictable partner and employer,” emphasizes Jānis Buks, Chairperson of the Management Board of JSC Olainfarm. J. Buks graduated from the Faculty of Law of the University of Latvia, obtaining a bachelor's degree in law. He improved his knowledge in

Arcadis reports transactions under its current share buyback program30.7.2021 12:00:00 CEST | Press release

Amsterdam, July 30, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 14,830 of its own shares in the period from 23 July up to and including 29 July 2021 at an average price of €36.99. The consideration of this repurchase was €0.5 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.5 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is the leading global desig